American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Return to Screening PDSA and Clinical Study: Frequently Asked Questions

As we continue with the second stage of the Return to Screening Plan/Do/Study/Act (PDSA) Clinical Study, questions have been coming in regarding the documentation of screening numbers and REDCap forms, as well as how to handle an increase in COVID-19 cases. Please review the frequently asked questions below to better assist your program.

FAQs for the Return to Screening PDSA and the Clinical Study

What do we do if we reach our target volume of screening in the first or second month?

It is important that you continue to monitor screening volumes each month from June to the end of November. If the intervention(s) you initiated is (are) working well and your monthly screening volumes continue to achieve or exceed your monthly target, then you may not need to initiate any other interventions. If the volumes drop below target, it is best to either reactivate the first intervention or initiate another intervention. Please continue to record your postintervention monthly screening rates through REDCap if you are participating in the clinical study or through the online forms if you are only participating in the PDSA.

What should we do if our program is being overwhelmed by the surge in COVID-19 cases?

Each accredited program must manage local cancer resources and screening efforts to the best of their ability. We expect programs to document within their cancer committee minutes the reasons behind curtailing screening and the specific circumstances involved, including timing of changes to participation in the Return to Screening PDSA. Please continue to record your postintervention monthly screening rates through REDCap if you are participating in the clinical study or through the online forms if you are only participating in the PDSA.

FAQs for Return to Screening PDSA Clinical Study

What should I do if I have not yet received or misplaced the REDCap Form B/C?

Only those programs participating in the clinical study that submitted REDCap Form A will have received Form B/C. If you are only participating in the PDSA, you will use the writeable forms available online and include these in your PRQ.

If you are participating in the clinical study, first check your spam/junk for an email from redcap@facs.org. The subject line is "Form B/C: Post-Intervention Monthly Data Collection and Intervention Log" and will also include the disease site in the subject line. If you cannot locate this email, please email Jessica Dangles at jdangles@facs.org and include the name and email of the individual who submitted the form as well as the disease site(s). The REDCap Form B/C can be opened and edited at any time before the final submission.

What if I submitted incorrect information on Form A or need to change the point of contact?

Please email Jessica Dangles at jdangles@facs.org and include the name and email of the individual who submitted the form as well as the disease site(s).

Cancer-Focused Sessions at Clinical Congress 2021—Register Today

ACS Clinical Congress 2021 is offering a variety of cancer-focused programming at this year's virtual event in addition to Cancer Programs-sponsored sessions. There are five days of cancer programming that you can participate in.

On Tuesday, October 26, Cancer Programs Medical Director, Heidi Nelson, MD, FACS, will be presenting the Herand Abcarian Lecture (NL05) at 9:00–9:55 am CDT.

From 9:00 am to 5:00 pm CDT on Saturday, October 23, and Sunday, October 24, there are scientific forums on various topics including breast, colon and rectal surgery, surgical oncology, geriatric and palliative care, hepatobiliary and pancreas, and fundamentals of oncoplastic breast surgery.

On Monday, October 25, 2:00–2:55 pm CDT, attend panel session PS363: Liver Transplantation for Colorectal Hepatic Metastatic Disease: Different Practices Around the World. This session will be moderated by Georgios Tsoulfas, MD, PhD, FACS and co-moderated by John J. Fung, MD, FACS.

Spend your lunch break Meeting the Expert 12:00–12:55 pm on Tuesday, October 26, to learn about Breast Cancer Management 2021. The moderator for this session is Lee G. Wilke, MD, FACS.

To learn more about the Cancer Programs-sponsored sessions and cancer programming during Clinical Congress, visit our web page and stay tuned to this newsletter as we highlight cancer programming at the virtual conference.